Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels.

ABSTRACT:

Background

We previously reported a Phase 1/2 randomized placebo-controlled trial of systemic administration of bone marrow-derived allogeneic MSCs (remestemcel-L) in COPD. While safety profile was good, no functional efficacy was observed. However, in view of growing recognition of effects of inflammatory environments on MSC actions we conducted a post-hoc analysis with stratification by baseline levels of a circulating inflammatory marker, C-reactive protein (CRP) to determine the effects of MSC administration in COPD patients with varying circulating CRP levels.

Methods

Time course of lung function, exercise performance, patient reported responses, and exacerbation frequency following four monthly infusions of remestemcel-L vs. placebo were re-assessed in subgroups based

SUBMITTER: Weiss DJ 

PROVIDER: S-EPMC8106850 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature